[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR038628A1 - Composicion oftalmica - Google Patents

Composicion oftalmica

Info

Publication number
AR038628A1
AR038628A1 ARP030100667A ARP030100667A AR038628A1 AR 038628 A1 AR038628 A1 AR 038628A1 AR P030100667 A ARP030100667 A AR P030100667A AR P030100667 A ARP030100667 A AR P030100667A AR 038628 A1 AR038628 A1 AR 038628A1
Authority
AR
Argentina
Prior art keywords
ascomycin
composition
ophthalm
blepharitis
epi
Prior art date
Application number
ARP030100667A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27791682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR038628A1 publication Critical patent/AR038628A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Composiciones oftálmicas tópicas, las cuales comprenden una ascomicina, por ejemplo, para el tratamiento de enfermedades inflamatorias, tales como blefaritis. Reivindicación 1: Una composición oftálmica, la cual comprende una ascomicina y un vehículo, el cual comprende un triglicérido de cadena mediana y/o miristato de isopropilo. Reivindicación 2: La composición de acuerdo con la reivindicación 1, en donde la ascomicina es 33-epi-cloro-33-desoxi-ascomicina.
ARP030100667A 2002-03-04 2003-02-28 Composicion oftalmica AR038628A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36151502P 2002-03-04 2002-03-04
US40927502P 2002-09-09 2002-09-09

Publications (1)

Publication Number Publication Date
AR038628A1 true AR038628A1 (es) 2005-01-19

Family

ID=27791682

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100667A AR038628A1 (es) 2002-03-04 2003-02-28 Composicion oftalmica

Country Status (28)

Country Link
US (4) US20050220823A1 (es)
EP (1) EP1482936B1 (es)
JP (1) JP4740542B2 (es)
KR (1) KR100992948B1 (es)
CN (1) CN1297270C (es)
AR (1) AR038628A1 (es)
AT (1) ATE341326T1 (es)
AU (1) AU2003218679B2 (es)
BR (1) BR0308184A (es)
CA (1) CA2477769C (es)
CO (1) CO5611133A2 (es)
DE (1) DE60308836T2 (es)
DK (1) DK1482936T3 (es)
EC (1) ECSP045277A (es)
EG (1) EG24403A (es)
ES (1) ES2274214T3 (es)
HK (1) HK1071301A1 (es)
IL (2) IL163657A0 (es)
MX (1) MXPA04008571A (es)
MY (1) MY137563A (es)
NO (1) NO20044092L (es)
NZ (1) NZ534690A (es)
PE (1) PE20030828A1 (es)
PL (1) PL210870B1 (es)
PT (1) PT1482936E (es)
RU (1) RU2322982C2 (es)
TW (1) TW200305437A (es)
WO (1) WO2003074054A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4463681B2 (ja) 2002-07-15 2010-05-19 アルコン，インコーポレイテッド 眼内使用のための非ポリマー親油性薬学的インプラント組成物
BR0312817A (pt) * 2002-07-23 2005-04-19 Novartis Ag Composição de pomada oftálmica compreendendo uma droga, uma base de pomada e um agente solubilizante/dispersante
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
BRPI0705564B8 (pt) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria sistema do tipo cristal líquido contínuo contendo co-solvente portador de substâncias fracamente solúveis em água, seu processo de obtenção e seus usos
EP2238878A1 (en) 2009-04-09 2010-10-13 Nestec S.A. Beverage preparation device having a closing mechanism with force demultiplying means
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
CA2761739C (en) 2009-05-12 2017-03-07 Galenica Ab Oil-in-water emulsion of mometasone and propylene glycol
MX2012007325A (es) * 2009-12-22 2012-07-20 Abbott Lab Capsula de abt-263.
EP2555748A2 (en) * 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
RU2531937C2 (ru) * 2012-05-14 2014-10-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазной мази
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
AU2013384818A1 (en) * 2013-03-27 2015-11-12 Comprehensive Drug Enterprises, Ltd. Ophthalmic composition, method for preparing the same, and use of the same
JP6448545B2 (ja) * 2013-11-29 2019-01-09 ロート製薬株式会社 眼科用又は耳鼻科用水性組成物
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US10606760B2 (en) * 2017-08-23 2020-03-31 Samsung Electronics Co., Ltd. Nonvolatile memory devices and methods of controlling the same
EP3741367A1 (en) 2019-05-21 2020-11-25 Premark Pharma GmbH Treatment of ocular disease
TW202432089A (zh) * 2023-01-31 2024-08-16 溫士頓醫藥股份有限公司 一種滴眼油劑型的醫藥組合物
WO2024209038A1 (en) 2023-04-06 2024-10-10 Premark Pharma Gmbh Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
DK0474126T3 (es) * 1990-09-04 1997-04-07 Fujisawa Pharmaceutical Co
PH31204A (en) * 1990-11-02 1998-05-05 Fujisawa Pharmaceutical Co Pharmaceutical composition.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CA2146006C (en) * 1993-08-18 2004-10-12 Louis Desantis, Jr. Use of ergoline derivatives for the treatment of glaucoma
CA2201134A1 (en) * 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
NZ331824A (en) * 1994-10-26 2000-01-28 Novartis Ag use of an unsaturated fatty alcohol to stabilise a macrolide in a pharmaceutical composition
FR2732598B1 (fr) * 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
FR2755852B1 (fr) * 1996-11-15 1998-12-24 Oreal Utilisation d'un alkylether de glycerol dans une composition cosmetique et/ou dermatologique comme actif pour le traitement de la seborrhee et de l'acne
KR100406823B1 (ko) * 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
DE60015516T2 (de) * 1999-04-30 2005-12-01 Sucampo Ag Verwendung von makroliden zur behandlung von trockenen augen

Also Published As

Publication number Publication date
CN1638769A (zh) 2005-07-13
TW200305437A (en) 2003-11-01
DK1482936T3 (da) 2007-01-08
CA2477769A1 (en) 2003-09-12
PT1482936E (pt) 2007-01-31
BR0308184A (pt) 2005-01-11
EG24403A (en) 2009-04-29
AU2003218679B2 (en) 2007-04-05
WO2003074054A1 (en) 2003-09-12
PL370917A1 (en) 2005-06-13
ATE341326T1 (de) 2006-10-15
MY137563A (en) 2009-02-27
IL163657A (en) 2009-11-18
NO20044092L (no) 2004-09-27
PL210870B1 (pl) 2012-03-30
US20120015971A1 (en) 2012-01-19
US20110152307A1 (en) 2011-06-23
CN1297270C (zh) 2007-01-31
CA2477769C (en) 2011-01-18
JP4740542B2 (ja) 2011-08-03
MXPA04008571A (es) 2004-12-06
RU2004129593A (ru) 2005-09-10
AU2003218679A1 (en) 2003-09-16
US20100113501A1 (en) 2010-05-06
EP1482936B1 (en) 2006-10-04
CO5611133A2 (es) 2006-02-28
JP2005529851A (ja) 2005-10-06
RU2322982C2 (ru) 2008-04-27
DE60308836D1 (de) 2006-11-16
ES2274214T3 (es) 2007-05-16
KR100992948B1 (ko) 2010-11-08
NZ534690A (en) 2007-06-29
KR20040094718A (ko) 2004-11-10
PE20030828A1 (es) 2003-11-04
ECSP045277A (es) 2004-10-26
US20050220823A1 (en) 2005-10-06
DE60308836T2 (de) 2007-04-26
HK1071301A1 (en) 2005-07-15
EP1482936A1 (en) 2004-12-08
IL163657A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
AR038628A1 (es) Composicion oftalmica
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
UY28222A1 (es) Inhibidores de citoquinas
ES2183937T3 (es) Inhibidores de la adhesion celular.
CL2010001486A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras.
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
HRP20040917B1 (hr) Topiäśki farmaceutski pripravci koji sadrže proantocijanide za tretman dermatitisa
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
HN2001000019A (es) Derivados de nicotinamida benzocondensada heterociclico utiles como inhibidores selectivos de las isozimas pde4.
ECSP11010949A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
PA8604201A1 (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
AR077372A1 (es) Composiciones y metodos para tratar infecciones oftalmicas oticas o nasales
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
PA8603001A1 (es) Compuestos utiles para el tratamiento de enfermedades
ECSP055844A (es) Nuevos compuestos triciclicos
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
EA200700044A1 (ru) Композиция для местного применения
UY29240A1 (es) Nuevos derivados de piridotienopirimidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure